BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

iCo-007: Phase II started

iCo said investigators began the U.S. Phase II iDEAL trial to evaluate intravitreal injections of iCo-007 alone and in combination with laser photocoagulation or ranibizumab. iCo has exclusive, worldwide...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >